Form DEF 14A Boston Scientific Corp For: 29 April
- Investing.com
Navigating Challenges | Delve into BSX's strategy to overcome tariff impacts and the TAVR exit, while leveraging its robust R&D capabilities to drive future innovations |
Analyst Optimism | With a consensus recommendation of 1.36, analysts project significant margin expansion and a weighted average market growth rate of 8.5% for 2025 |
Strategic Acquisitions | Explore BSX's expansion into high-growth areas like renal denervation and neuromodulation through strategic acquisitions of SoniVie and Axonics |
Market Dominance | Boston Scientific's impressive 21.44% revenue growth and 20% organic growth highlight its strong market position and effective growth strategies |
Metrics to compare | BSX | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipBSXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 23.6x | 24.7x | −0.5x | |
PEG Ratio | 0.32 | 0.37 | 0.00 | |
Price / Book | 3.5x | 4.9x | 2.6x | |
Price / LTM Sales | 4.1x | 3.4x | 3.2x | |
Upside (Analyst Target) | 49.5% | 27.5% | 47.8% | |
Fair Value Upside | Unlock | 11.7% | 6.7% | Unlock |